Bal Pharma Limited

NSEI:BALPHARMA Voorraadrapport

Marktkapitalisatie: ₹2.1b

Bal Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO Bal Pharma is Shailesh Siroya, benoemd in Aug2019, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 10.20M, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 19.27% van de aandelen van het bedrijf, ter waarde ₹ 399.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 4.5 jaar.

Belangrijke informatie

Shailesh Siroya

Algemeen directeur

₹10.2m

Totale compensatie

Percentage CEO-salaris100.0%
Dienstverband CEO5.3yrs
Eigendom CEO19.3%
Management gemiddelde ambtstermijn4.2yrs
Gemiddelde ambtstermijn bestuur4.5yrs

Recente managementupdates

Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Sep 19
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Sep 18
Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Sep 19
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet

Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20

Aug 31
Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20

Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Aug 27
Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year

Aug 15
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year

Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price

May 30
Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price

Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Mar 14
Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?

Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

Feb 01
Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up

Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Sep 18
Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment

Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Aug 28
Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Aug 14
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Aug 17
Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00

Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Jul 31
Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00

Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Mar 08
Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?

Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Nov 23
Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky

Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?

Aug 10
Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?

Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?

Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?

Analyse CEO-vergoeding

Hoe is Shailesh Siroya's beloning veranderd ten opzichte van Bal Pharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

₹77m

Jun 30 2024n/an/a

₹76m

Mar 31 2024₹10m₹10m

₹74m

Dec 31 2023n/an/a

₹35m

Sep 30 2023n/an/a

₹32m

Jun 30 2023n/an/a

₹24m

Mar 31 2023₹12m₹12m

₹26m

Dec 31 2022n/an/a

₹29m

Jun 30 2022n/an/a

₹43m

Mar 31 2022₹10m₹10m

₹56m

Dec 31 2021n/an/a

₹72m

Jun 30 2021n/an/a

₹59m

Mar 31 2021₹10m₹10m

₹47m

Dec 31 2020n/an/a

-₹34m

Sep 30 2020n/an/a

-₹73m

Jun 30 2020n/an/a

-₹95m

Mar 31 2020₹10m₹10m

-₹122m

Dec 31 2019n/an/a

-₹52m

Sep 30 2019n/an/a

-₹15m

Jun 30 2019n/an/a

-₹21m

Mar 31 2019₹8m₹8m

₹38m

Dec 31 2018n/an/a

₹29m

Mar 31 2018₹8m₹8m

₹28m

Compensatie versus markt: De totale vergoeding ($USD 120.82K ) Shailesh } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 42.64K ).

Compensatie versus inkomsten: De vergoeding van Shailesh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Shailesh Siroya (58 yo)

5.3yrs

Tenure

₹10,200,000

Compensatie

Mr. Shailesh Dheerajmal Siroya serves as the Managing Director of BAL Pharma Limited. Mr. Siroya served as the Managing Director of BAL Pharma Limited since August 1, 1994. With rich experience, Mr. Siroya...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Shailesh Siroya
MD & Executive Director5.3yrs₹10.20m19.27%
₹ 399.1m
Daddanala Bharath Bhushan
Chief Financial Officerno data₹2.60mgeen gegevens
Abdul Basith
Company Secretary & Compliance Officer1.3yrs₹540.00kgeen gegevens
Himesh Virupakshaya
Whole Time Director4.2yrs₹3.32m0.17%
₹ 3.5m
Ravindra Kothari
Deputy General Manager of Internal Auditno datageen gegevensgeen gegevens
D. Bhat
Assistant Vice President of Sales & Marketingno datageen gegevensgeen gegevens
Archana Mitra
Vice President of International Marketing & HRno data₹534.34kgeen gegevens
Kotian Damodar
Whole Time Directorno data₹1.87mgeen gegevens

4.2yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BALPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Shailesh Siroya
MD & Executive Director27.2yrs₹10.20m19.27%
₹ 399.1m
Himesh Virupakshaya
Whole Time Director5.2yrs₹3.32m0.17%
₹ 3.5m
Kotian Damodar
Whole Time Director2.5yrs₹1.87mgeen gegevens
Nicola Neeladrie
Independent Non-Executive Director4.5yrs₹52.00kgeen gegevens
H. Venkatesh
Non-Executive Additional Independent Director4.5yrs₹61.00kgeen gegevens
Jatish Sheth
Non-Executive Independent Director3.9yrs₹61.00kgeen gegevens

4.5yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BALPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).